[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357312-105":59,"doc-detail-357312-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","antineoplastic-agent-associated-interstitial-lung-disease-in-breast-ovarian-and-prostate-cancers-a-pharmacovigilance-study-using-the-fda-adverse-event-reporting-system","Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers - a pharmacovigilance study using the FDA adverse event reporting system","","Interstitial lung disease (ILD) is a potentially fatal adverse effect of anticancer therapy, yet comparative ILD reporting associations across antineoplastic agents in sex hormone-sensitive solid tumors remain unclear. This study compares ILD reporting associations among antineoplastic agents used in breast, ovarian, and prostate cancers by analyzing FAERS reports for 65 prespecified agents using disproportionality analysis, multivariable regression, and time-to-onset methods, and by conducting a structured PubMed search through March 15, 2026 for eligible human case reports. T-DXd showed the strongest ILD signal, with additional elevated signals for agents such as darolutamide and fulvestrant. Age and body weight were independently associated, and findings support early ILD monitoring while requiring cautious interpretation and confirmation in prospective studies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antineoplastic-agent-associated-interstitial-lung-disease-in-breast-ovarian-and-prostate-cancers-a-pharmacovigilance-study-using-the-fda-adverse-event-reporting-system/357312/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antineoplastic-agent-associated-interstitial-lung-disease-in-breast-ovarian-and-prostate-cancers-a-pharmacovigilance-study-using-the-fda-adverse-event-reporting-system/357312.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study?","Question",{"text":112,"@type":113},"To compare ILD reporting associations among antineoplastic agents used in breast, ovarian, and prostate cancers and to add external clinical context from published literature.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which data sources were used to evaluate ILD associations?",{"text":117,"@type":113},"The study analyzed FAERS reports for ILD linked to 65 prespecified antineoplastic agents and performed a structured PubMed search through March 15, 2026 for eligible human case reports and case series.",{"name":119,"@type":110,"acceptedAnswer":120},"Which agent showed the strongest ILD signal in the FAERS analysis?",{"text":121,"@type":113},"Trastuzumab deruxtecan (T-DXd) showed a prominent ILD signal and the highest adjusted reporting association.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},357312,1790219753,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Original Research PUBLISHED 10 June 2026  \nDOI 10.3389/fimmu.2026.1840323  \nOPEN ACCESS  \nEDITED BY  \nSerafeim-Chrysovalantis Kotoulas, Geniko Nosokomeio Thessalonikes Ippokrateio, Greece  \nREVIEWED BY  \nDechao Feng,  \nUniversity College London, United Kingdom  \nLing Yin,  \nHefei Comprehensive National Science Center Data Space Research Institute, China  \n*CORRESPONDENCE  \nYu Ren  \n [renyyyyy@126.com](renyyyyy@126.com)[ ](renyyyyy@126.com)Lizhe Zhu  \n[zhulizhe0301@163.com](zhulizhe0301@163.com)[ ](zhulizhe0301@163.com)RECEIVED 27 March 2026 REVISED 12 May 2026 ACCEPTED 27 May 2026 PUBLISHED 10 June 2026  \nCITATION  \nDu K, Duan C, Zhang J, Zhang J, Du J, Pan Y, Liu Z, Zhang C, Zhang Y, Zhang Y, Zhang X, Sheng Z, Wang B, Ren Y and Zhu L (2026) Antineoplastic agentassociated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system.  \nFront. Immunol. 17:1840323 .  \ndoi: 10.3389/fimmu.2026.1840323  \nCOPYRIGHT  \n© 2026 Du, Duan, Zhang, Zhang, Du, Pan, Liu, Zhang, Zhang, Zhang, Zhang, Sheng, Wang, Ren and Zhu. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAntineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system  \nKeyuan Du 1,2, Chenglong Duan 1,2, Jiaqi Zhang 1,2, Jianing Zhang 1,2, Jinsui Du 1,2, Yi Pan 1,2, Zhihao Liu 1,2, Chenrong Zhang 1,2, Yuhan Zhang 1,2, Yibin Zhang 1,2, Xuan Zhang 1,2, Zhongxia Sheng 1,2, Bin Wang 1, Yu Ren 1* and Lizhe Zhu 1*  \n1 Department of Breast Surgery, The First Afﬁliated Hospital of Xi’an Jiaotong University, Xi ’an,  \nShaanxi, China, 2The First Clinical School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, China  \nInterstitial lung disease (ILD) is a potentially fatal adverse effect of anticancer therapy, but comparative ILD reporting associations across antineoplastic agents in sex hormone-sensitive solid tumors (breast, ovarian, and prostate cancers) remain unclear. This study aimed to compare ILD reporting associations among antineoplastic agents used in these malignancies and to provide external clinical context from the published literature. We analyzed FAERS reports of ILD associated with 65 prespeciﬁed antineoplastic agents used in patients with sex hormone-sensitive solid tumors. Each drug ’s ILD reporting association was evaluated using disproportionality analysis (reporting odds ratios), multivariable regression, and time-to-onset analyses. In addition, we conducted a structured PubMed search through March 15, 2026 for eligible human case reports and case series involving these agents. Among 8,146 FAERS ILD reports, trastuzumab deruxtecan (T-DXd) showed a prominent ILD signal and the highest adjusted reporting association. Some sex hormone-pathway agents, including darolutamide and fulvestrant, also showed elevated ILD reporting associations, and concomitant SHA analyses identiﬁed additional signals. Older age and lower body weight were independently associated with ILD reporting. In exploratory complete-case TTO analyses, death-recorded ILD reports showed a shorter median reported TTO than non–death-recorded ILD reports; in FDR-adjusted body-weight–stratiﬁed analyses, this pattern was observed in the ≥70 kg subgroup but not in the \u003C70 kg subgroup and should be interpreted as hypothesis-generating. The literature review identiﬁed 85 eligible publications comprising 98 case-level records and provided supportive clinical context for the FAERS ﬁndings. Overall, ILD reporting associations v","cbCaihZEeZJkbwHd","https://ap.wps.com/l/cbCaihZEeZJkbwHd","pdf",5875384,15,"English","# Introduction\n## Interstitial lung disease as a serious anticancer adverse event","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To compare ILD reporting associations among antineoplastic agents used in breast, ovarian, and prostate cancers and to add external clinical context from published literature.\"},{\"question\":\"Which data sources were used to evaluate ILD associations?\",\"answer\":\"The study analyzed FAERS reports for ILD linked to 65 prespecified antineoplastic agents and performed a structured PubMed search through March 15, 2026 for eligible human case reports and case series.\"},{\"question\":\"Which agent showed the strongest ILD signal in the FAERS analysis?\",\"answer\":\"Trastuzumab deruxtecan (T-DXd) showed a prominent ILD signal and the highest adjusted reporting association.\"}]","Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers - a pharmacovigilance study using the FDA adverse event reporting system | PDF",1790129593,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dd14696ca67a52b626aa5fcb5214f42.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a246ddfd8d602aa70cacfcdc3b6ad55c.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/baae7164c616010b7a7adb474afb901b.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9049ecc47a86a936d0f7ca97b248ecc8.webp",980,1385]